Merck/Ridgeback’s Lagevrio Could Get Another Chance As Others Face Limitations

New Analysis Shows No COVID-19 At Days 3 Or 5

 
• By Alaric DeArment
  
Merck & Co. and Ridgeback are presenting a new analysis at ECCMID for Lagevrio in COVID-19 • Source: Alamy
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from COVID-19

More from Scrip